SCHEMBL19089512

SCHEMBL19089512

C=CC(=O)Nc1cc(Nc2cc(Nc3ccc(F)c(Cl)c3)ncn2)c(OC)cc1OCCN1CCCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 17/20 0.56
ERBB3 P21860 3/20 0.56
DUS2 Q9NX74 1/20 0.56
ERBB2 P04626 6/20 0.56
ERBB4 Q15303 6/20 0.56
SRC P12931 3/20 0.56
KIT P10721 2/20 0.56
GAK O14976 2/20 0.56
RIPK2 O43353 2/20 0.56
LCK P06239 2/20 0.56
JAK3 P52333 2/20 0.56
RIPK3 Q9Y572 2/20 0.56
KDR P35968 2/20 0.56
BMPR1B O00238 1/20 0.56
CIT O14578 1/20 0.56
MAP2K7 O14733 1/20 0.56
EPHB6 O15197 1/20 0.56
MAP3K7 O43318 1/20 0.56
STK17B O94768 1/20 0.56
STK10 O94804 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL35210333 1.00 EGFR (0.56) EGFRERBB3DUS2ERBB2ERBB4
SCHEMBL20548833 0.95 EGFR (0.58) EGFRERBB3DUS2ERBB2ERBB4
SCHEMBL35210271 0.95 EGFR (0.58) EGFRERBB3DUS2ERBB2ERBB4
SCHEMBL19089545 0.94 EGFR (0.66) EGFRERBB3DUS2ERBB2ERBB4
SCHEMBL35210266 0.94 EGFR (0.66) EGFRERBB3DUS2ERBB2ERBB4
SCHEMBL20548915 0.93 EGFR (0.56) EGFRERBB3DUS2ERBB2ERBB4
SCHEMBL35210316 0.93 EGFR (0.56) EGFRERBB3DUS2ERBB2ERBB4
SCHEMBL19089546 0.88 EGFR (0.62) EGFRERBB3DUS2ERBB2KDR
SCHEMBL20656038 0.87 EGFR (0.54) EGFRERBB2ERBB4SRCGAK
SCHEMBL19089517 0.86 EGFR (0.59) EGFRERBB3DUS2ERBB2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3398939-B1 ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY ANCUREALL PHARMACEUTICAL SHANGHAI CO LTD (CN) 2026-05-06 EP claimed
CN-106928150-B Acrylamide aniline derivative and pharmaceutical application thereof 恩瑞生物医药科技(上海)有限公司 2020-07-31 CN claimed
US-10342796-B2 Acrylanilide derivative, preparation method, and applications thereof in pharmacy ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) 2019-07-09 US claimed
US-20190015413-A1 ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) 2019-01-17 US claimed
EP-3398939-A1 ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY Ancureall Pharmaceutical (Shanghai) Co., Ltd. (CN) 2018-11-07 EP claimed
EP-3398939-B1 ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY ANCUREALL PHARMACEUTICAL SHANGHAI CO LTD (CN) 2026-05-06 EP disclosed
US-10342796-B2 Acrylanilide derivative, preparation method, and applications thereof in pharmacy ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) 2019-07-09 US disclosed
US-10342796-B2 Acrylanilide derivative, preparation method, and applications thereof in pharmacy ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) 2019-07-09 US disclosed
US-20190015413-A1 ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) 2019-01-17 US disclosed
US-20190015413-A1 ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) 2019-01-17 US disclosed
EP-3398939-A1 ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY Ancureall Pharmaceutical (Shanghai) Co., Ltd. (CN) 2018-11-07 EP disclosed
WO-2017114500-A1 ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY 恩瑞生物医药科技(上海)有限公司 2017-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10342796-B2 Acrylanilide derivative, preparation method, and applications thereof in pharmacy EGFR, ABL1, CSNK1A1 EGFR 1/4885ERBB3 8/4885DUS2 2790/4885
US-20190015413-A1 ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY EGFR, ABL1, CSNK1A1 EGFR 1/4885ERBB3 8/4885DUS2 2790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.